Carlos A. Sariol to Dengue Vaccines
This is a "connection" page, showing publications Carlos A. Sariol has written about Dengue Vaccines.
Connection Strength
0.618
-
Chen RE, Smith BK, Errico JM, Gordon DN, Winkler ES, VanBlargan LA, Desai C, Handley SA, Dowd KA, Amaro-Carambot E, Cardosa MJ, Sariol CA, Kallas EG, S?kaly RP, Vasilakis N, Fremont DH, Whitehead SS, Pierson TC, Diamond MS. Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell Host Microbe. 2021 11 10; 29(11):1634-1648.e5.
Score: 0.201
-
Stauft CB, Song Y, Gorbatsevych O, Pantoja P, Rodriguez IV, Futcher B, Sariol CA, Wimmer E. Extensive genomic recoding by codon-pair deoptimization selective for mammals is a flexible tool to generate attenuated vaccine candidates for dengue virus 2. Virology. 2019 11; 537:237-245.
Score: 0.174
-
Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, Sariol CA, Shek LP, Simasathien S, Smith MK, Velez ID, Wallace D, Gordon GS, Stinchcomb DT. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. J Infect Dis. 2016 May 15; 213(10):1562-72.
Score: 0.134
-
White LJ, Sariol CA, Mattocks MD, Wahala M P B W, Yingsiwaphat V, Collier ML, Whitley J, Mikkelsen R, Rodriguez IV, Martinez MI, de Silva A, Johnston RE. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J Virol. 2013 Mar; 87(6):3409-24.
Score: 0.110